文献速递消化系统肿瘤

S-1与吉西他滨辅助化疗对切除后胰腺癌健康相关生活质量的对比:JASPAC 01随机III期试验结果

Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
PubMed 文献 · Eur J Cancer · 2018-03-20

JASPAC 01试验中,S-1辅助化疗较吉西他滨延长了切除后胰腺癌患者生存,本研究评估两者对健康相关生活质量(HRQOL)的影响。385例随机患者中354例纳入HRQOL分析,使用EQ-5D量表在基线、3、6个月及之后每6个月评估。结果显示治疗开始6个月内两组EQ-5D指数变化相似,但12至24个月S-1组更优,且质量调整生命月更长。

要点

  • 治疗开始6个月内S-1与吉西他滨的EQ-5D指数变化相似(差异0.024,P=0.112)。
  • 12至24个月期间S-1组EQ-5D指数变化优于吉西他滨组(差异0.071,P<0.001)。
  • S-1组质量调整生命月长于吉西他滨组(P<0.001)。

核心结论

  • S-1辅助化疗在治疗开始6个月内未改善HRQOL,但此后改善HRQOL并延长质量调整生命月。

研究设计与样本

  • JASPAC 01随机III期试验的HRQOL分析,385例随机患者中354例纳入分析。
  • 患者随机接受吉西他滨(1000 mg/m2,每周一次,每4周用3周,最多6周期)或S-1(40、50或60 mg,每日两次,每6周用4周,最多4周期)。
  • 使用EQ-5D-3L问卷在基线、3个月、6个月及之后每6个月评估HRQOL。

主要发现

  • 治疗开始6个月内两组EQ-5D指数平均变化相似(差异0.024,P=0.112)。
  • 12至24个月期间S-1组EQ-5D指数平均变化优于吉西他滨组(差异0.071,P<0.001)。
  • 同期S-1组行动能力和疼痛/不适问题发生率低于吉西他滨组。
  • S-1组质量调整生命月长于吉西他滨组(P<0.001)。

临床怎么用

  • 对于切除后胰腺癌患者,S-1辅助化疗在长期HRQOL和质量调整生存方面可能优于吉西他滨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant chemotherapy with S-1 for resected pancreatic cancer demonstrated survival benefits compared with gemcitabine in the JASPAC 01 trial. We investigated the effect of these agents on health-related quality of life (HRQOL) of patients in the JASPAC 01 trial. METHODS: Patients with resected pancreatic cancer were randomly assigned to receive gemcitabine (1000 mg/m2 weekly for three of four weeks for up to six cycles) or S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles). HRQOL was assessed using the EuroQol-5D-3L (EQ-5D) questionnaire at baseline, months three and six, and every 6 months thereafter. HRQOL end-points included change in EQ-5D index from baseline, responses to five items in the EQ-5D, and quality-adjusted life months up to 24 months. RESULTS: Of randomised 385 patients, 354 patients were included in HRQOL analysis. Mean change in the EQ-5D index was similar in the S-1 and gemcitabine groups within 6 months from treatment initiation (difference, 0.024; P = 0.112), whereas corresponding mean from 12 to 24 months was better in the S-1 group than in the gemcitabine group (difference, 0.071; P < 0.001). Problems in mobility and pain/discomfort were also less frequent in the S-1 group than in the gemcitabine group in that period. Quality-adjusted life months were longer in the S-1 group than in the gemcitabine group (P < 0.001). CONCLUSION: Adjuvant chemotherapy with S-1 does not improve HRQOL within 6 months from treatment initiation but does improve HRQOL thereafter and quality-adjusted life months. CLINICAL TRIAL REGISTRATION NUMBER: UMIN000000655 at UMIN CTR.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hagiwara Y, Ohashi Y, Uesaka K, et al. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). Eur J Cancer. 2018. PMID: 29477795. doi:10.1016/j.ejca.2018.01.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。